Testing a new Alzheimer's treatment in early-stage patients

Plain-English translation of NCT07328451 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new medication called to see if it is safe and tolerable for people with early Alzheimer's disease or mild cognitive impairment caused by amyloid buildup in the brain. About 68 participants will be enrolled across multiple centers. Half will receive the medication at increasing doses, and half will receive a placebo (inactive pill) to compare effects.

Alzheimer's disease is a serious condition that damages memory and thinking. Researchers are looking for new treatments that might help slow or stop this damage by targeting amyloid, a protein that builds up abnormally in the brains of people with Alzheimer's. This trial will help determine whether this new treatment could be a safe option for patients in the early stages of the disease.

Do you qualify?

You likely qualify if…

you have been diagnosed with early Alzheimer's disease or mild cognitive impairment with evidence of amyloid buildup in your brain
you have a Mini-Mental State Examination score between 20 and 30
you have a BMI between 18 and 32 and weigh at least 45 kg (about 99 pounds)
you do not have other serious neurological or psychiatric conditions besides Alzheimer's
you have not previously received anti-amyloid or anti-tau immunotherapy (certain other Alzheimer's treatments)

You likely don't qualify if…

you have other serious brain or mental health conditions besides Alzheimer's disease
you have uncontrolled heart disease, lung disease, liver disease, or other major medical conditions
you have had cancer within the past 5 years (except for certain low-risk types)
you have previously received gene therapy
you are currently taking medications or have conditions that would interfere with study safety or results

What participation looks like

You will visit a study clinic multiple times over several months to receive the medication or placebo by mouth at increasing doses. At each visit, the study team will check your safety through blood tests, brain imaging, cognitive tests, and physical exams. You will be randomly assigned to either receive the medication or placebo, and neither you nor the study staff will know which you received until the trial ends, ensuring unbiased results.

AI-generated summary from trial data · Jul 10, 2026 · Not medical advice

Trial locations(4 sites)

Netherlands

Clinical Site(s), 's-Hertogenbosch

Clinical Site(s), Amsterdam

Clinical Site(s), Zwolle

United Kingdom

Clinical Site(s), London